Clinical Trial Update: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET [Phase 2]

View source ↗

Summary

Phase 2 trial of the HSP90 inhibitor AUY922 in myeloproliferative neoplasms including primary myelofibrosis and MF after PV/ET was terminated. Results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Polycythemia Vera
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• AUY922 (luminespib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Myeloproliferative Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2016-05-23